NEW YORK, March 07, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Omega Protein Corp. (“Omega” or the “Company”) (NYSE: OME) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Omega securities between August 3, 2016 and March 1, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/ome.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) the SEC is requesting information in connection with an investigation relating to Omega’s subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees; (2) it is possible that the foregoing matter could result in a material adverse effect on Omega’s business, reputation, results of operation and financial condition; and (3) consequently, Defendants’ statements about Omega’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
On March 1, 2017, post-market, Omega revealed that it had received a subpoena from the U.S. Securities and Exchange Commission seeking information about an investigation of Omega subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees. Following this news, Omega stock dropped as much as $5.86 per share, or 22.32%, during intraday trading on March 2, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ome or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Omega you have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 



